Method of Treating Nitrate-induced Tolerance

Details for Australian Patent Application No. 2004200573 (hide)

Owner Pfizer Ireland Pharmaceuticals

Inventors Ellis, Peter

Agent Spruson & Ferguson

Pub. Number AU-B-2004200573

Parent 767452

Filing date 13 February 2004

Wipo publication date 11 March 2004

Acceptance publication date 8 February 2007

International Classifications

C07D 239/88 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61K 31/4985 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

A61K 31/505 (2006.01) - Pyrimidines

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61K 31/5377 (2006.01)

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

C07D 471/14 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

26 February 2004 Complete Application Filed

11 March 2004 Application Open to Public Inspection

  Published as AU-B-2004200573

23 June 2005 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

29 September 2005 Section 223 Application Received

  Pfizer Research and Development Company, N.V./S.A. An application to extend the time from 30 Nov 2004 to 30 Jun 2005 in which to pay a continuation fee has been filed . Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

17 November 2005 Section 223 Application Allowed

  Pfizer Research and Development Company, N.V./S.A. The time in which to pay a continuation fee has been extended to 30 Jun 2005. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

20 July 2006 Assignment before Grant

  Pfizer Research and Development Company, N.V./S.A. The application has been assigned to Pfizer Ireland Pharmaceuticals

8 February 2007 Application Accepted

  Published as AU-B-2004200573

7 June 2007 Standard Patent Sealed

26 June 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004200574-Controlling Release of Active Agents from a Chewing Gum Coating

2004200572-Frozen aerated product